| Abstrakt: |
Antiviral drugs for the treatment of COVID-19 patients: applications of drug monitoring B M. Tempestilli b I UOSD Immunologia Cellulare e Farmacologia e UOS Professioni Sanitarie Tecniche i I Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Roma. i In the last years, several studies on new and/or repurposing antiviral drugs were initiated to fight Coronavirus disease 2019 (COVID-19) pandemic. Continuing through the years to the present day we can see many examples of personalized therapy that are current practice today: hemopoietic stem cell transplantation, infectious diseases prophylaxis and treatment, GvHD biomarkers, targeted drug levels, pre-emptive therapy on specific molecular targets, integration of targeted therapy inside transplantation program both as bridging therapy and early maintenance post-transplant particularly in acute myeloid leukemia because of the several mutation recognized determining clonal heterogeneity and drug resistance. The POCT in the development of a clinical assistance network in proximity medicine B U M. Mele u , P. Coppolecchia b I Dipartimento Interaziendale di Medicina di Laboratorio, AUSL Modena i Point of care (POC) are tests conducted near the site of patient care, outside of laboratory, usually performed by patients or healthcare personnel not trained in laboratory medicine. Therefore, the monitoring of drug concentration of antivirals against SARS-CoV2 could be pivotal to optimise drug regimens, increase efficacy and avoid drug-related toxicity and to evaluate intra-individual variability and drug-drug interactions. [Extracted from the article] |
